Online ISSN 2313-1519
Print    ISSN 1812-2892
Abstract - Ursodeoxycholic acid: paradigmatic transformation of the prevention of drug-induced liver lesions in clinical practice
[PDF]            [Full text/HTML]           
Maksim Potjagenko, Anna Nevoit, Oksana Kitura

ABSTRACT

In the article argued the necessity of using tactics “hepatoprotektor’s escort” in clinical practice. In it demonstrates data about new effects of Ursodeoxycholic Acid and the capabilities of its application as a universal hepatoprotector have been elucidated. Inclusion of Ursodeoxycholic Acid in the combined therapy enhances the effectiveness of treatment of patients in many branches of medicine.
Keywords: Ursodeoxycholic Acid - drug-induced liver lesions

REFERENCES

1. Zhuravleva L.V., Kryvonosova E.M., Lopyna N.A. Use of Ursodeoxycholic Acid in Internal Medicine. Praktykuiuchyi likar. 2014; 4:25-32.

2. Potjagenko M.M., Nevoit A.V., Service hepatoprotective therapy by Ursodeoxycholic Acid. Health of Ukraine. 2007; 18: 69-71.

4. Aagaard K, Petrosino J, Keitel W, Watson M, Katancik J, Garcia N, Patel S, Cutting M, Madden T, Hamilton H, Harris E. The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. The FASEB Journal. 2013; 1;27(3):1012-22.

https://doi.org/10.1096/fj.12-220806

5. Ridlon JM, Bajaj JS. The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics. Acta Pharmaceutica Sinica B. 2015; 31;5(2):99-105.

6. Thiessen K. Die Wirkung von Ursodeoxycholsäure auf die Cholesterin-und Gallensäurebiosynthese (Doctoral dissertation, lmu).

7. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. Journal of hepatology. 2001; 1;35(1):134-46.

https://doi.org/10.1016/S0168-8278(01)00092-7

8. Paumgartner G. Importance of bile acids in the pathogenesis and therapy of hepatic diseases. Cholestatic Liver Disease, 2004; 111 p.

9. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002; 1;36(3):525-31.

https://doi.org/10.1053/jhep.2002.36088

10. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 2000; 1;32(6):1196-9.

https://doi.org/10.1053/jhep.2000.20240

11. Abdelkader NF, Safar MM, Salem HA. Ursodeoxycholic acid ameliorates apoptotic cascade in the rotenone model of Parkinson's disease: modulation of mitochondrial perturbations. Molecular neurobiology. 2016; 1;53(2):810-7.

https://doi.org/10.1007/s12035-014-9043-8

12. Maksymova E.V., Kliarytskaia Y.L. Hepatoxicity at patients of a rheumatic profile: features of a current, possibility of correction. Krumskyi terapevtycheskyi zhurnal. 2015; 1(24):58-64.

13. Moon SJ, Jeong JH, Jhun JY, Yang EJ, Min JK, Choi JY, Cho ML. Ursodeoxycholic acid ameliorates pain severity and cartilage degeneration in monosodium iodoacetate-induced osteoarthritis in rats. Immune network. 2014; 1;14(1):45-53.

https://doi.org/10.4110/in.2014.14.1.45

14. Dubreuil M, Ruiz‐Gaspà S, Gua-abens N, Peris P, Álvarez L, Monegal A, Combalia A, Parés A. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. Liver international. 2013; 1;33(7):1029-38. doi: 10.1111/liv.12153. [Epub ahead of print]
https://doi.org/10.1111/liv.12153

15. Otte C.M., Rothuizen J., Favier R.P et al. A morphological and immunohistochemical study of the effects of prednisolone or ursodeoxycholic acid on liver histology in feline lymphocytic cholangitis. J. Feline Med. Surg. 2014; 16(10):796-804.
https://doi.org/10.1177/1098612X14520811

16. Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J, Nihtinen A, Hägglund H, Ringdén O, for Blood NG. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biology of Blood and Marrow Transplantation. 2014; 31;20(1):135-8. doi: 10.1016/j.bbmt.2013.10.014. [Epub ahead of print]
https://doi.org/10.1016/j.bbmt.2013.10.014

17. Troisi G, Crisciotti F, Gianturco V, D'Ottavio E, Lo IC, Formosa V, Bernardini S, Bellomo A, Marigliano B, Marigliano V. The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case-control study. La Clinica terapeutica. 2012;164(3):203-7.

18. Mortiboys H, Furmston R, Bronstad G, Aasly J, Elliott C, Bandmann O. UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2G2019S carriers and in vivo. Neurology. 2015; 8;85(10):846-52.

https://doi.org/10.1212/WNL.0000000000001905

19. Cortez LM, Campeau J, Norman G, Kalayil M, Van der Merwe J, McKenzie D, Sim VL. Bile acids reduce prion conversion, reduce neuronal loss, and prolong male survival in models of prion disease. Journal of virology. 2015; 1;89(15):7660-72.

https://doi.org/10.1128/JVI.01165-15

20. Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, Hass P, Wust P, Kropf S, Gademann G, Ricke J. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PloS one. 2014; 13;9(11):e112731.

https://doi.org/10.1371/journal.pone.0112731

21. De A.K., Sana S., Datta S. et al. Protective efficacy of ursodeoxycholic acid nanoparticles in animal model of inflammatory bowel disease. Microencapsul. 2014; 31(8):370-725.
https://doi.org/10.3109/02652048.2014.918666

22. Belonovskaya E.B., Naruta E. E., Lukivskaya O.YA. et al. Profilakticheskoe primenenie novyh proizvodnyh ursodeoksiholevoj kisloty (UDHC) pri ehksperimental'nom alkogol'nom steatogepatit. Zhurnal ehksperimental'noj i klinicheskoj farmakologii. 2013; 1:25-29.

23. Vang S., Longley K., Steer C.J., Low W.C. The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Glob. Adv. Health Med. 2014; 3(3):58-69.
https://doi.org/10.7453/gahmj.2014.017

24. Weingarden A.R.,Chen C., Zhang N. Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated with the Infection. J. Clin. Gastroenterol. 2016; 50 (8):30 – 624.
https://doi.org/10.1097/MCG.0000000000000427

25. Wieser V., Gerner R., Moschen A.R., Tilq H. Liver complications in inflammatory bowel diseases. Diq D.K. 2013; 3(2):233-238.
https://doi.org/10.1159/000353377

 

Volume 1, Number 43 (2017)